MARKETS / COMPANIES / ECONOMYRSS edition ↗
Capital Ledger
Market News

Scientists pioneer revolutionary test to tackle global superbug crisis

Sydney duo Alison Todd and Elisa Mokany are leading the fight against one of the world’s biggest silent killers, antimicrobial resistance, in an effort to prevent humanity from slipping “back to the dark ages”.Known as…

Scientists pioneer revolutionary test to tackle global superbug crisis

Sydney duo Alison Todd and Elisa Mokany are leading the fight against one of the world’s biggest silent killers, antimicrobial resistance, in an effort to prevent humanity from slipping “back to the dark ages”.

Known as the quiet pandemic, antimicrobial resistance (AMR) happens when drugs, including antibiotics, antivirals and antifungals, no longer halt bacteria and viruses, fuelling the rise of superbugs. They have been named in The List: Top 100 Innovators 2026.

Overuse of these drugs is threatening to undermine health systems globally, with the World Health Organisation estimating AMR kills about 4.7 million people a year. That fatality rate is forecast to almost double by 2050.

But Dr Todd and Dr Mokany – who have more than 100 patents between them – have an answer.

The pair founded SpeeDx 16 years ago and have developed a test to ensure effectiveness of a drug before and during treatment, becoming pioneers of “resistance-guided therapy” to combat the scourge of overprescriptions to quash superbugs and even cancer.

The US has become their biggest customer, representing about 90% of their business, which has received backing from America’s National Institutes of Health as part of a broader group to fight antimicrobial resistance.

“You don’t realise how much antibiotics are used every day. In hospitals, going to surgery, there is so much use of antibiotics. If we lost that … it would send us back to the dark ages,” Dr Mokany said.

The pair are featured in this year’s The List: Top 100 Innovators, which was published online on Friday.

Antimicrobial resistance soars

Antimicrobial resistance has soared in the past 20 years. For example, in 2005 drugs were able to cure mycoplasma genitalium (mgen), a sexually transmitted infection, about 85% of the time. But in 2013 the cure rate crashed to 52%.

“They were just detecting the bacteria, giving it first line treatment, and it was not working. And the cure rate plummeted. It was really significant,” Dr Mokany said.

Around the same time, SpeeDx – which develops specialised, real-time polymerase chain reaction assay technologies to detect DNA and RNA targets, identify specific pathogens, and pinpoint antibiotic resistance markers – was in its infancy.

“We developed upon request of the researchers and the clinician this test, because we just invented our technology at that time,” Dr Mokany said.

“And so they did a study and looked at using our test to guide therapy. So they call it resistance-guided therapy, and the cure rate increased up to 95 per cent.

“So by having the results upfront to guide treatment, they went from 52 per cent failure to 95 per cent cure, and that’s really revolutionised this space of testing and treating in STIs.”

As a result, regulators in Europe and the UK changed their guidelines to ensure resistance-guided therapy was administered first for treating mgen. It has also become the standard treatment for other bacteria, and SpeeDx is also expanding into cancer.

“Twenty years before it became mainstream, we did some of the very, very first testing that actually showed you could detect a mutation associated with a solid tumour, like a colorectal cancer, and you could pick it up in blood,” Dr Todd said.

“We had the vision to see it coming a long way off, and sometimes it takes a fair while for the world to catch up and to actually believe in what we believe.”

But despite SpeeDx’s success, challenges remain, particularly in gaining traction in Australia.

Fighting big pharma

“Our best customers are global. We’ve had products on the market where we could have revolutionised testing with NSW Health or other health departments, and worse international tests were chosen over us.

“Had we had government support trying to instigate our tests, it would have saved the country a lot of money. It just didn’t happen, and I think there’s a real culture in Australia not to support Australian and not to buy Australian.”

Dr Todd said it wasn’t so much a belief that internationalism was better, it was more the economics of fighting big pharma.

“If we’re a small Australian company and we’re up against some global giant, they can come in and package a whole range. So they’re prepared to almost take a cut on one of their products because they get their whole range into the system,” Dr Todd said.

“And so they just charge us a silly price just to make sure that we don’t get in at all.”

Dr Mokany and Dr Todd said Australia could emulate the US’s National Institutes of Health model, which funds clinical studies to bring different companies together to combat health threats such as antimicrobial resistance.

“That’s what Australia needs to do. We need these products. Let’s put some funding in. Bring a few companies through to do these clinical studies and launch these products. It would make a huge difference,” Dr Mokany said.

The Australian’s Top 100 Innovators was published Friday, November 6. Check out the full list here.

This article first appeared in The Australian as Sydney scientists pioneer revolutionary test to tackle global superbug crisis.

The post Scientists pioneer revolutionary test to tackle global superbug crisis appeared first on Stockhead.

Source: Stockhead — Australian Stock Market ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.